𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? - A literature-based meta-analysis

✍ Scribed by Chongrui Xu, Qing Zhou, Yi-long Wu

Book ID
119913652
Publisher
BioMed Central
Year
2012
Tongue
English
Weight
465 KB
Volume
5
Category
Article
ISSN
1756-8722

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

OP78 EGFR mutations based on circulating
OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)
✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 40 KB